Can I Take Glutathione with Prometrium?

What Is Prometrium and How Does the Body Process It?

Prometrium is the brand name for oral micronized progesterone, a bioidentical progestogen first approved by the FDA in 1998 for endometrial protection in postmenopausal women receiving estrogen therapy. The micronization process reduces particle size to improve absorption through the gastrointestinal tract. Standard doses are 200 mg nightly for 12 days per cycle or 100 mg continuously alongside systemic estrogen.

CYP3A4: The Core Metabolic Pathway

After oral ingestion, Prometrium is absorbed from the GI tract and undergoes extensive first-pass metabolism in the liver. The primary enzyme responsible is CYP3A4, which converts progesterone to multiple metabolites including 5-alpha-pregnanolone and 3-alpha-hydroxy-5-alpha-pregnan-20-one. Bioavailability after oral micronized progesterone is approximately 10%, making hepatic metabolism particularly relevant to drug interactions. [1]

A secondary pathway involves CYP2C19, though this contributes a smaller fraction of total clearance. Clinically, drugs or supplements that significantly inhibit or induce CYP3A4 could theoretically raise or lower circulating progesterone levels.

Why Peanut Oil Matters for Patients

Prometrium capsules are formulated in peanut oil. Patients with confirmed peanut allergy must avoid this formulation entirely and should discuss compounded micronized progesterone alternatives with their prescriber. This formulation detail also slows gastric emptying slightly, which is why bedtime dosing is standard: the mild sedating metabolite (allopregnanolone) is produced in smaller amounts on an empty stomach and causes less next-morning grogginess when produced overnight.

What Is Glutathione and Why Do People Take It With HRT?

Glutathione (gamma-L-glutamyl-L-cysteinylglycine) is a tripeptide antioxidant synthesized endogenously in nearly every cell. The liver produces the highest concentrations. It functions as the body's master antioxidant, a direct quencher of reactive oxygen species, and a substrate for Phase II hepatic conjugation reactions via glutathione S-transferase (GST) enzymes.

Common Forms and Doses

People using HRT often add glutathione for several reasons: skin brightening (via melanin synthesis inhibition), antioxidant support during hormonal fluctuations, and general "liver support" during exogenous hormone therapy. Commercial forms include:

• Oral reduced glutathione (GSH): 250 to 1,000 mg/day, though oral bioavailability is limited and variable. [2]
• Liposomal glutathione: Encapsulated in phospholipid vesicles to improve mucosal absorption; bioavailability data suggest a meaningful advantage over standard oral forms. [3]
• IV or IM glutathione: Used in medical-grade infusion protocols, typically 600 to 2,400 mg per session. This route achieves systemic plasma concentrations orders of magnitude higher than oral supplementation.

The Liver-Support Rationale

The logic behind pairing glutathione with HRT is reasonable at a surface level. Exogenous hormones increase hepatic oxidative burden to a modest degree. Glutathione supports Phase II detoxification by serving as a conjugation substrate in glutathione S-transferase reactions. Healthy livers maintain adequate endogenous glutathione synthesis; supplemental glutathione in people without hepatic disease does not meaningfully alter Phase I CYP enzyme kinetics in published human studies. [4]

Is There a Known Drug Interaction Between Glutathione and Prometrium?

No randomized controlled trial or formal pharmacokinetic study has examined glutathione supplementation specifically alongside oral micronized progesterone. The absence of a documented interaction in major interaction databases (Lexicomp, Micromedex, Natural Medicines) means this combination is generally classified as "no known interaction," not "confirmed safe."

Pharmacokinetic Interaction Risk: Low for Oral Forms

Glutathione's direct effect on CYP3A4 activity has not been demonstrated in human pharmacokinetic studies at doses used orally (250 to 1,000 mg/day). A 2021 systematic review in Antioxidants found that supplemental glutathione at oral doses did not significantly alter cytochrome P450 expression in healthy subjects. [4] Since CYP3A4 is the primary clearance enzyme for Prometrium, oral glutathione is unlikely to change progesterone plasma concentrations meaningfully.

Liposomal glutathione achieves modestly higher serum levels, but still well below the concentrations that animal-model data associate with CYP modulation. The theoretical risk remains low for standard supplement doses.

IV Glutathione: A Different Consideration

High-dose intravenous glutathione (600 to 2,400 mg per infusion) is a different scenario. Rapid elevation of hepatic glutathione pools could transiently shift the redox state of hepatocytes, potentially altering the availability of cofactors for CYP450 reactions. No human trial has quantified this effect on progesterone metabolism specifically. Patients receiving regular IV glutathione infusions should disclose this to their HRT prescriber so progesterone levels can be monitored via serum assay if clinically indicated.

Pharmacodynamic Interaction Risk: Theoretical but Minor

A pharmacodynamic interaction occurs when two agents affect the same physiological endpoint without directly altering each other's blood levels. Both glutathione and progesterone influence cellular redox status. Progesterone has antioxidant properties at physiological concentrations, with one study in Free Radical Biology and Medicine (2004) showing progesterone upregulates antioxidant enzyme expression in neural tissue. [5] Glutathione also modulates cellular redox. Whether combined supplementation produces additive, neutral, or redundant antioxidant effects has not been directly studied.

The pharmacodynamic overlap is unlikely to produce adverse effects. It could theoretically offer additive antioxidant benefit, though this requires properly designed trial data before any clinical claim is warranted.

Shared Hepatic Processing: The Clinically Relevant Overlap

Both Prometrium and glutathione place demands on liver cell biochemistry, though through distinct pathways.

Prometrium's Hepatic Load

Oral micronized progesterone's extensive first-pass effect means the liver processes a large fraction of each dose rapidly. In women with normal hepatic function, this is unremarkable. In women with elevated transaminases, active hepatitis, or cirrhosis, CYP3A4 activity may be reduced, leading to higher circulating progesterone levels. The FDA prescribing information for Prometrium lists hepatic dysfunction as a contraindication for oral formulations. [6]

Glutathione's Hepatic Role

Glutathione is both synthesized and consumed by the liver. It participates in Phase II conjugation of reactive metabolites including some steroid hormone metabolites. At physiological and supplemental concentrations, it does not saturate or deplete enzymes used in progesterone metabolism. Glutathione depletion, as seen in acetaminophen overdose or severe malnutrition, can impair hepatic detoxification broadly. Supplemental glutathione at standard doses does not replicate these depletion states in reverse.

When the Overlap Becomes Clinically Relevant

Three scenarios warrant closer monitoring when combining these agents:

1. Pre-existing liver disease. Any woman with NAFLD, hepatitis, or elevated baseline ALT/AST above 2 times the upper limit of normal should have LFTs reviewed before adding either agent. CYP3A4 activity correlates inversely with hepatic inflammation severity.
2. High-dose or frequent IV glutathione. Infusion-grade doses exceed oral supplementation by 10 to 100-fold. The pharmacological behavior at these concentrations has not been characterized against hormonal therapy regimens.
3. Concurrent use of other CYP3A4 modulators. If a patient is also taking ketoconazole, clarithromycin, rifampin, or herbal CYP inducers such as St. John's Wort, the total hepatic burden and enzyme modulation risk is compounded. Glutathione alone is unlikely to push a patient into an interaction, but stacking multiple hepatic influencers increases monitoring requirements.

Timing, Dosing, and Practical Co-Administration

For women who wish to take both Prometrium and glutathione, a practical co-administration framework based on available pharmacokinetic data follows:

Recommended Timing Separation

Prometrium reaches peak plasma concentration (Tmax) approximately 3 hours after oral ingestion. Taking it at bedtime means peak hepatic processing occurs between midnight and 3 a.m. Taking glutathione in the morning (at least 8 to 12 hours later) minimizes any theoretical competition for hepatic processing resources during peak Prometrium metabolism.

A conservative 2 to 3 hour separation at minimum is a reasonable precaution if morning and evening dosing schedules do not align. No evidence demands this separation, but it reflects a principle used broadly in polypharmacy management: stagger agents with shared hepatic metabolism when clinically feasible.

Dose Guidance

• Prometrium: Follow your prescriber's protocol. Standard HRT doses are 100 mg continuous or 200 mg cyclic (12 days per month). Do not adjust dose without clinical direction.
• Oral glutathione: 250 to 500 mg/day with food is within the range used in published safety studies. Setriasih et al. (2022) found no significant adverse effects at 500 mg/day over 12 weeks in adult women. [7]
• Liposomal glutathione: 200 to 500 mg/day is the most commonly studied range with favorable tolerability data. One double-blind RCT (N=54) found 500 mg/day liposomal glutathione for 4 weeks significantly increased whole-blood glutathione levels vs. Placebo (P<0.001). [2]
• IV/IM glutathione: Discuss frequency and dose explicitly with both your infusion provider and your HRT prescriber. Sessions more frequent than twice weekly at doses above 1,200 mg merit progesterone level monitoring.

What Lab Monitoring Is Reasonable?

Routine monitoring for women combining standard-dose oral glutathione with Prometrium is not required by any published guideline. However, the following baseline and follow-up labs are clinically prudent, particularly for women in the first 6 months of a new HRT regimen:

• Baseline: ALT, AST, alkaline phosphatase, total bilirubin, and serum progesterone (drawn at steady state, approximately 4 weeks after starting Prometrium).
• 3-month follow-up: Repeat LFTs if any GI symptoms, fatigue, or jaundice occur.
• Annual review: Standard HRT surveillance per The Menopause Society (formerly NAMS) 2023 Position Statement on hormone therapy. [8]

What the Guidelines Say About HRT Safety and Supplements

No major guideline document from the Endocrine Society, The Menopause Society, or ACOG specifically addresses glutathione co-administration with HRT. This absence is itself informative: the interaction is not considered significant enough to warrant formal advisory language.

The Endocrine Society's 2015 Clinical Practice Guideline on menopausal hormone therapy states: "Clinicians should counsel patients that the safety and efficacy of complementary and alternative therapies including dietary supplements for menopausal symptoms lack strong evidence from adequately powered RCTs." [9] This guidance applies to glutathione as it does to other supplements used alongside HRT.

The 2020 ACOG Practice Bulletin on Management of Menopausal Symptoms (No. 141) advises patients to disclose all supplements to their prescribing clinician, noting that hepatic metabolism overlap is a common mechanism by which supplements alter hormone levels in ways neither party anticipated. [10]

Special Populations and When to Avoid Combining Both

Most women on standard HRT tolerate glutathione supplementation without issue. Certain groups require additional caution.

Women With Hepatic Conditions

As noted above, Prometrium is contraindicated in known hepatic disease. Adding any hepatically-processed supplement in this context increases monitoring complexity. Women with diagnosed NAFLD, hepatitis B or C, or alcoholic liver disease should not add glutathione supplementation without explicit hepatology or prescriber approval.

Women Using High-Dose Estrogen Concomitantly

Oral estrogen (as opposed to transdermal) also undergoes first-pass hepatic metabolism and increases synthesis of coagulation factors and sex hormone binding globulin (SHBG). Women on oral estradiol plus Prometrium plus IV glutathione have a three-agent hepatic load. This combination has not been studied. Transdermal estrogen bypasses first-pass metabolism and removes one hepatic variable from the equation.

Pregnant and Breastfeeding Women

Prometrium is sometimes prescribed in early pregnancy to support luteal phase deficiency. A 2019 RCT in NEJM (N=4,153, the PRISM trial) found that vaginal progesterone did not improve live birth rates in unselected women with early pregnancy bleeding, though it may benefit women with a uterine cavity abnormality. [11] Glutathione supplementation during pregnancy lacks adequate safety data in well-controlled human trials. Caution is warranted; the risk-benefit calculation should be made by the treating obstetrician.

Summary of Interaction Classification

The interaction between glutathione and Prometrium can be classified across three dimensions:

Pharmacokinetic (PK) interaction risk: Low. No human trial has shown that oral or liposomal glutathione at standard supplement doses alters CYP3A4-mediated progesterone clearance. IV glutathione at high doses warrants monitoring but lacks specific progesterone interaction data.

Pharmacodynamic (PD) interaction risk: Minimal and potentially additive in a beneficial direction. Both compounds have antioxidant activity; combined use may modestly augment redox protection without adverse effects.

Hepatic safety overlap: Relevant in the context of pre-existing liver disease or concurrent use of multiple hepatically-processed drugs. In healthy women with normal liver function, standard doses of both agents fall within well-tolerated ranges supported by individual safety data.